Bayer Prevails in Baycol Deceptive Marketing Class Action



DOCUMENTS
  • Opinion


CHICAGO - To maintain an action against a drug maker under the Illinois Consumer Fraud and Deceptive Business Practices Act, a plaintiff must actually be deceived by a statement or omission by the defendant and the mere sale of a prescription drug is not a representation that the drug is safe for its intended use, the state high court has ruled. De Bouse v. Bayer, No. 107528 (Ill. Sup. Ct.).

In a Dec. 17 opinion, the Illinois Supreme Court concluded that a state trial court erred in denying Bayer's motion for summary judgment on claims that it deceptively marketed its …






UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Hotel Details in Tucson, Arizona, to be Announced

MORE DETAILS